Table 3.
Effects of mesenchymal stem cells derived from bone marrow and adipose tissue on nerve fibre density in TNBS-induced colitis
| Sham | TNBS | TNBS + BM-MSC | TNBS + AT-MSC | |
|---|---|---|---|---|
| Level of CGRP immunoreactivity/1 mm2 (%) | ||||
| 24 h | 12.0 ± 0.1 | 6.3 ± 0.6 †††† | 9.5 ± 0.5 *** †† | 8.5 ± 0.4 * ††† |
| 72 h | 12.2 ± 0.4 | 6.1 ± 0.4 †††† | 9.6 ± 0.7 *** †† | 9.4 ± 0.3 *** †† |
| Density of TH-IR nerve fibres/1 mm2 (%) | ||||
| 24 h | 17.2 ± 0.8 | 11.6 ± 0.4 †† | 17.4 ± 0.1 ** | 16.8 ± 0.9 ** |
| 72 h | 17.4 ± 1.1 | 12.6 ± 0.4 †† | 17.0 ± 1.3 * | 17.5 ± 1.2 ** |
| Density of VAChT-IR nerve fibres/1 mm2 (%) | ||||
| 24 h | 19.9 ± 0.9 | 11.6 ± 0.8 †††† | 20.3 ± 0.5 **** | 19.9 ± 0.2 **** |
| 72 h | 20.5 ± 1.1 | 12.9 ± 0.4 †††† | 19.6 ± 0.7 **** | 20.0 ± 0.6 **** |
TNBS 2,4,6-trinitrobenzene sulfonic acid, BM-MSC bone marrow derived mesenchymal stem cells, AT-MSC adipose tissue derived mesenchymal stem cells, CGRP calcitonin gene-related peptide, TH tyrosine hydroxylase, VAChT vesicular acetylcholine transporter, IR immunoreactive
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, significantly different to TNBS; ††p < 0.01, †††p < 0.001, ††††p < 0.0001, significantly different to sham